Eculizumab for drug-induced de novo posttransplantation thrombotic microangiopathy: A case report.
De novo thrombotic microangiopathy (TMA) following renal transplantation is a severe complication associated with high rates of allograft failure. Several immunosuppressive agents are associated with TMA. Conventional approaches to managing this entity, such as withdrawal of the offending agent and/or plasmapheresis, often offer limited help, with high rates of treatment failure and graft loss. We herein report a case of drug induced de novo TMA successfully treated using the C5a inhibitor eculizumab in a renal transplant patient. This report highlights a potentially important role for eculizumab in settings where drug-induced de novo TMA is refractory to conventional therapies.
Kassem
K
Safa
Merranda S
MS
Logan
Ibrahim
I
Batal
Steven
S
Gabardi
Helmut G
HG
Rennke
Reza
R
Abdi
D000328:Adult; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects; D016030:Kidney Transplantation / Q000009:adverse effects / Q000379:methods*; D008297:Male; D016559:Tacrolimus / Q000008:administration & dosage / Q000009:adverse effects*; D057049:Thrombotic Microangiopathies / Q000139:chemically induced / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology
D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; C481642:eculizumab; D016559:Tacrolimus